All enrolled clients who gained not less than one dose of zosuquidar or placebo for the duration of induction have been monitored to the occurrence of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The most typical adverse situations were related to the duration of prolonged and https://lsklinhibitorofthrombospo76543.blogstival.com/50530561/the-best-side-of-3